XML 69 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Recognition - Schedule of Revenue by Geographic Location (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
 [1]
Sep. 28, 2019
 [2]
Jun. 29, 2019
 [3]
Mar. 30, 2019
 [3]
Dec. 31, 2018
Sep. 29, 2018
 [4]
Jun. 30, 2018
 [5]
Mar. 31, 2018
 [6]
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]                      
Net sales $ 1,322.8 $ 1,191.1 $ 1,149.0 $ 1,174.5 $ 1,195.2 $ 1,133.1 $ 1,186.4 $ 1,217.0 $ 4,837.4 [7] $ 4,731.7 [7] $ 4,946.2 [7]
United States                      
Disaggregation of Revenue [Line Items]                      
Net sales [7]                 3,225.6 3,098.3 3,272.3
Europe                      
Disaggregation of Revenue [Line Items]                      
Net sales [7],[8]                 1,335.8 1,347.6 1,343.6
All other countries                      
Disaggregation of Revenue [Line Items]                      
Net sales [7],[9]                 276.0 285.8 330.3
Ireland                      
Disaggregation of Revenue [Line Items]                      
Net sales                 $ 23.4 $ 25.7 $ 30.4
[1] Includes impairment charges of $141.6 million.
 
First
Quarter
 
Second
Quarter (2)
 
Third
Quarter (3)
 
Fourth
Quarter
Year Ended December 31, 2018
 
 
 
 
 
 
 
Net sales
$
1,217.0

 
$
1,186.4

 
$
1,133.1

 
$
1,195.2

Gross profit
$
492.7

 
$
471.0

 
$
424.8

 
$
443.0

Change in financial assets
$
9.6

 
$
(0.6
)
 
$
(74.9
)
 
$
(122.8
)
Net income (loss)
$
80.8

 
$
36.2

 
$
(67.5
)
 
$
81.5

Earnings (loss) per share(1):
 
 
 
 
 
 
 
Basic
$
0.57

 
$
0.26

 
$
(0.49
)
 
$
0.60

Diluted
$
0.57

 
$
0.26

 
$
(0.49
)
 
$
0.60

Weighted average shares outstanding:
 
 
 
 
 
 
 
Basic
140.8

 
138.1

 
137.4

 
135.9

Diluted
141.4

 
138.7

 
137.4

 
136.3
[2] ludes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.(4) Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.
[3]
Includes change in financial assets of $10.4 million.
[4]
Includes impairment charges of $221.8 million and restructuring charges and other termination benefits of $18.0 million.
[5]
Includes acquisition-related charges and contingent consideration adjustments of $53.2 million.
[6] The sum of individual per share amounts may not equal due to rounding.
[7] The net sales by geography is derived from the location of the entity that sells to a third party.
[8]
Includes Ireland net sales of $23.4 million, $25.7 million, and $30.4 million for the years ended December 31, 2019, December 31, 2018, and December 31, 2017, respectively.
[9] Includes revenue generated primarily in Israel, Mexico, Australia, and Canada.